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Histone acetylation deficits in lymphoblastoid cell
lines from patients with RubinsteineTaybi syndrome
J P Lopez-Atalaya,1 C Gervasini,2 F Mottadelli,2 S Spena,2 M Piccione,3 G Scarano,4
A Selicorni,5 A Barco,1 L Larizza2
ABSTRACT
Background RubinsteineTaybi syndrome (RSTS) is
a congenital neurodevelopmental disorder defined by
postnatal growth deficiency, characteristic skeletal
abnormalities and mental retardation and caused by
mutations in the genes encoding for the transcriptional
co-activators with intrinsic lysine acetyltransferase (KAT)
activity CBP and p300. Previous studies have shown that
neuronal histone acetylation is reduced in mouse models
of RSTS.
Methods The authors identified different mutations at
the CREBBP locus and generated lymphoblastoid cell
lines derived from nine patients with RSTS carrying
distinct CREBBP mutations that illustrate different grades
of the clinical severity in the spectrum of the syndrome.
They next assessed whether histone acetylation levels
were altered in these cell lines.
Results The comparison of CREBBP-mutated RSTS cell
lines with cell lines derived from patients with an
unrelated mental retardation syndrome or healthy
controls revealed significant deficits in histone
acetylation, affecting primarily histone H2B and histone
H2A. The most severe defects were observed in the lines
carrying the whole deletion of the CREBBP gene and the
truncating mutation, both leading to a haploinsufficiency
state. Interestingly, this deficit was rescued by treatment
with an inhibitor of histone deacetylases (HDACi).
Conclusions The authors’ results extend to humans the
seminal observations in RSTS mouse models and point to
histone acetylation defects, mainly involving H2B and
H2A, as relevant molecular markers of the disease.
INTRODUCTION
RubinsteineTaybi syndrome (RSTS; Online
Mendelian Inheritance in Man #180849, #613684)
is a poorly understood autosomal-dominant disorder
that affects one out of 125 000 newborns.1 The
disease is characterised by postnatal growth retar-
dation, cognitive impairment, skeletal abnormalities
and a high incidence of neoplasia.2 3 Individuals
with RSTS experience difﬁculty in planning and
executing motor acts and have a short attention
span and a low intelligence level with an average IQ
of 50, although mental range can go from 25 to
80.4 5 The distinctive anatomical features, including
facial dysmorphisms, hypertelorism, prominent
nose, malpositioned ears and especially broad
thumbs and toes, are commonly used for diagnosis
that can be conﬁrmed by genetic screen. Two genes
are currently known to be responsible for RSTS:
CREBBP encoding for the cAMP response element-
binding protein (CREB)-binding protein (also
known as CBP) and located at 16p13.36 and EP300
encoding for the E1A associated protein p300, highly
homologous to CBP, and located at 22q13.7 Frame-
shift, nonsense, splice site and missense point
mutations in the CREBBP locus (in decreasing order
of prevalence) are found in about 50% of RSTS
cases,6e18 whereas deletions of part or all of the
CREBBP gene and ﬂanking regions may account for
an additional 5%e10% of the cases.13 19 20 A few
gene-disrupting translocations and inversions have
been also reported.6 19 21e25 EP300 mutations are
comparatively rare. Only seven cases have been
described so far in patients with a mild clinical
presentation.7 26e29
CBP and p300 are transcriptional co-activators
with intrinsic lysine acetyltransferase activity30
(KAT, previously referred to as histone acetyl-
transferase,31 HAT) that act in different signal
transduction pathways and are involved in the
control of cell growth, cellular differentiation, DNA
repair, apoptosis and tumour suppression.32 33 They
also play an important role in the development of
the skeletal and central nervous systems. Although
little is still known about the speciﬁc epigenetic
modiﬁcations associated to this syndrome, as well
as its relative signiﬁcance in terms of transcrip-
tional defects, the deﬁciency on KATactivity during
development and in adulthood seems to be the
most likely cause of RSTS symptoms.
Studies in mouse models of RSTS have provided
valuable information on RSTS aetiology and
revealed a critical role for CBP’s KAT activity in
cognitive processes.34e38 These studies have shown
that the loss or reduction of CBP is associated with
reduced bulk levels of histone acetylation in the
brain. In cbp+/ mice, the model that better repro-
duces the genetic alteration found in most patients
with RSTS, the acetylation of histone H2B is
particularly affected,36 whereas in neurons of CBP
conditional knockouts, all four histones are affected,
but the deﬁcit in acetylation is still stronger in the
case of histones H2B and H2A.39e41 No signiﬁcant
reduction of bulk histone acetylation was observed in
the hippocampus of p300 hemizygous mice, which
show very mild cognitive deﬁciencies, strengthening
the correlation between reduced neuronal histone
acetylation and cognitive impairments.42
The main objective of this study is to investigate
whether histone acetylation is also affected in
patients with RSTS. Towards this end, we have
selected a group of patients with RSTS who carry
different molecular lesions of CREBBP and are
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therefore representative of the main types of causative mutations.
We obtained lymphoblastoid cell lines from these patients and
examined the consequences of the mutation in bulk histone
acetylation. The results of these experiments extend our seminal
ﬁndings in crebbp mutant mice and revealed that histone acety-
lation deﬁcits are concomitant with cognitive impairments also in
humans.
MATERIALS AND METHODS
Patients
One hundred ten individuals clinically diagnosed as having RSTS
were genetically tested for mutations of the CREBBP gene. This
scan identiﬁed a cohort of CREBBP-positive patients with RSTS,
consisting of 43 patients carrying heterozygous point mutations
and 7 carrying deletions in one allele. Among these cases, we
selected nine patients representative of the wide clinical vari-
ability of the syndrome and its allelic heterogeneity. They all
show skeletal abnormalities with broad thumb or hallux and have
typical facial features of RSTS with psychomotor and mental
retardation ranging from mild to severe. Malformations and other
signs of the disease were reported in some patients. See table 1 for
additional details. The patients with Cornelia de Lange syndrome
(CdLS) all carry heterozygous mutations in the NIPBL gene.
Molecular test of CREBBP mutation and bioinformatic analysis
As a ﬁrst step in our study, we performed ﬂuorescence in situ
hybridisation (FISH) analysis to detect total or partial deletions
in the CREBBP gene in those samples in which chromosome
spreads could be set up. Then, we screened the coding region of
the CREBBP gene by denaturing high-performance liquid chro-
matography (DHPLC) and direct sequencing. Bacterial artiﬁcial
chromosome-FISH (BAC-FISH) on the genomic region
harbouring CREBBP gene and DHPLC/DNA sequencing of all
coding exons of CREBBP were performed as previously
described.12 20 Reverse transcriptase-PCR (RT-PCR) analysis of
mutated alleles was also performed as previously described.12 All
the detected mutations were searched and conﬁrmed in the
corresponding cell lines. BAC clones for FISH analysis were
selected according to Genome Browser (http://genome.ucsc.edu).
PCR conditions for DHPLC screening were determined using the
software Optimase Protocol Writer. ClustalW2 (http://www.ebi.
ac.uk/Tools/clustalw2/index.html) was used to analyse the
amino acidic sequence alignment of human CBP versus
Drosophila, Caenorhabditis elegans and murine CBP, and versus
human p300. PolyPhen (http://coot.embl.de/PolyPhen) was used
for prediction of the possible effect of any amino acid substi-
tution, and the Splice Site Prediction by Neural Network (http://
www.fruitﬂy.org/seq_tools/splice.htm) tool at the Berkeley
Drosophila Genome Project was used to predict the conse-
quences of mutations affecting putative splicing donor or
acceptor sites.
Cell lines establishment, maintenance and treatment
Lymphoblastoid cell lines from all patients and healthy indi-
viduals were established by EpsteineBarr virus transformation
of peripheral blood mononuclear cells, in collaboration with
Galliera Genetic Bank (Istituto Galliera, Genoa, Italy). All cells
were grown in RPMI 1640 media (Sigma, Saint Louis, MI, USA)
supplemented with 2 mM L-glutamine, 10% fetal bovine serum
(Invitrogen, Camarillo, CA, USA) and penicillin/streptomycin.
In trichostatin A (TSA) experiments, cells were incubated for 2 h
with vehicle (dimethyl sulfoxide (DMSO)) or 2 mM TSA in fresh
media. This treatment did not affect cell viability in the time
frame of our experiments.
Quantitative RT-PCR
Total cellular RNA isolation was performed using RNeasy kit
(Qiagen Inc., Chatsworth, CA, USA). Reverse transcription was
performed using RevertAid First Strand cDNA synthesis kit
(Fermentas, St. Leon-Rot, Germany). Quantitative RT-PCR
(qRT-PCR) was carried out on a ABI 7300 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA) and ampliﬁed
using SYBR GreenER qPCR reagent (Invitrogen). Each sample
was assayed in duplicate and normalised using GAPDH levels.
Primer sequences for ampliﬁcation of CBP, p300 and GAPDH
transcripts were designed using Primer Express Software V.2.0
(Applied Biosystems).
Quantitative western blotting
Western blot analyses were carried out as previously described.43
The following home-made and commercial primary antibodies
and dilutions were used: rabbit anti-histone H2B (1:10000) and
mouse anti-histone H3 (1:10 000) (Abcam, Cambridge, UK),
mouse anti b-actin (Sigma) (1:50 000); anti-acetylated histone
H2A (AcH2A) (1:1000), anti-acetylated histone H2B (AcH2B)
(1:10 000), anti-acetylated histone H3 (1:10 000) and anti-acet-
ylated histone H4 (AcH4) (1:1000).43 Secondary antibodies were
anti-mouse HRP (1:10 000) and anti-rabbit HRP (1:10 000)
(Sigma).
Fluorescent activated cell sorting (FACS) analysis
Cells (1e53106 cells) were ﬁxed overnight in 70% ethanol
solution at 208C, pelleted and washed twice with staining
buffer (phosphate-buffered saline with 1% fetal bovine serum).
A total of 13105 cells per condition were incubated with rabbit
anti-acetyl histone H2B for 30 min at room temperature. Cells
were washed and then stained with an Alexa Fluor 488-conju-
gated goat anti-rabbit antibody (Invitrogen) for 20 min at room
temperature in the dark. Washes and staining steps were
performed using staining buffer. Background staining was
determined in negative cell lines and with matched ﬂuoro-
chrome-conjugated isotype controls. Cells were analysed on
a FACSAria III ﬂow cytometer (BD biosciences, Franklin Lakes,
NJ, USA).
Statistical methods
Precise description of the statistical methods used in each
experiment is presented in the text. In the graphs, error bars
represent SEM.
RESULTS
Characterisation of novel CREBBP mutations and transcript
analysis in peripheral blood and lymphoblastoid cell lines from
patients with RSTS
To investigate the acetylation state of the chromatin of cells
from patients with RSTS, we obtained lymphoblastoid cells
lines from peripheral blood of patients of special interest based
on their clinical features and/or the nature of their molecular
pathogenetic lesions. These patients were selected from a large
cohort of 110 patients diagnosed as having RSTS recruited from
different Italian clinical units and screened for mutations in
CREBBP. Among the 50 patients whose clinical diagnosis could
be conﬁrmed by molecular and/or FISH analysis of the CREBBP
gene, nine were selected for further study through the genera-
tion of lymphoblastoid cell lines. This panel of patients with
RSTS is representative of the different clinical manifestations of
the syndrome, as detailed in table 1, and of the allelic hetero-
geneity at the CREBBP locus. The genetic lesions carried by the
selected patients include a whole gene deletion and eight point
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Table 1 Clinical signs of the nine cell line donor patients as compared to those characteristic of patients with RSTS
Patient 41 75 99 114 20 46 98 84 127
Mutation/type Whole gene
deletion
microdeletion
c.2556delC
p.Gln786ArgfsX21
truncating
c.85+1G/T
splicing
c.4485-
7C/G
splicing
c.4728+
1G/A
splicing
c.4627G/T
p. Asp1543Tyr
missense
c.2014G/C
p.Leu1338Phe
missense
c.5060C/T
p.Ser1687Phe
missense
c.4444T/G
p.Tyr1482Asp
missense
Age/sex 30 y/F 14 y/M 4 y/M 4 y/M 15 y/F 7 y/F 9 y/M 7 y/F 15 y/F
Age at diagnosis 20 y Birth Birth 20 m Birth 20 m 5 y 5 y 2 y
Growth
IUGR  +       
Birth weight (g) NA 3230 3400 3430 3080 2840 2830 3340 2750
Postnatal weight NA 258 NA <108 NA <38 >958 258 <38
Postnatal height <38 108 NA <108 <38 <38 <38 258 <38
Feeding problems + NA NA  NA NA  + +
Psychomotor development
Sitting position 12 m NA NA 10 m 12 m NA 13 m 7 m 16 m
First walk 24 m NA NA 17 m 30 m NA 18 m 16 m 16 m
First words 3 y NA NA 20 m 20 m NA 24 m 4 y 4 y
First sentences  NA NA   + 3 y  NA
Severity of MR Severe Moderatee
severe
NA Severe Severe Mild Mild Moderatee
severe
Moderatee
severe
Behavioural
problems
Attention
deficit
disorder
NA NA  Autism
spectrum
disorder
NA   Attention
deficit
disorder
Typical dysmorphisms
Microcephaly +  + + + +  + +
Prominent forehead  +  + +  +  +
Downslanting
palpebral fissures
+ +  + + + +  
Prominent backed
nose
 + + + + + + + +
Columella below
the alae nasi
+ + + + + + + + +
Grimacing smile  +  +     +
High and vaulted
palate
  + + +  +  
Micrognathia +  + +    + 
Hirsutism  +    +   +
Hands
Broad thumb + + + + + + + + +
Bifid thumb  +       
Radial deviation of
thumb
+ NA NA    +  
Other Polydactyly Ulnar
deviation
Feet
Broad hallux + + + + + + + + +
Bifid hallux     +    
Other 
Major malformations
Heart anomalies   NA ASD     Fallot
tetralogy
Ocular anomalies      NA   
Genital anomalies   Cryptorchidism      
Kidney anomalies      Vesicoureteral
reflux, renal
hypoplasia
 Hydronephrosis Vesicoureteral
reflux
Medical complications
Ocular problems Myopia,
strabismus
 NA   NA  Strabismus 
Dental problems   NA   NA   Malocclusion
Hypoacusia   NA      
Orthopaedic
problems
Scoliosis  NA Genu valgus,
pes planus
Patellar
luxation
NA   
Keloids   NA      
Neoplasia Forehead
haemangioma
 NA   Multiple
pilomatrixoma
lesions
  
Other Obesity
Continued
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mutations: four missense, three splicing and a truncating
mutation. Three out of these nine mutations have been previ-
ously described,12 20 while the characterisation of the remaining
six patients is presented here for the ﬁrst time.
Missense mutations
All missense mutations were de novo as they were searched
and excluded in the probands’ parents and in 50 healthy indi-
viduals. Patient 46 (c.4627G/T, p.D1543T in exon 28) has been
previously described,12 while patients 84, 98 and 127 are carriers
of novel missense mutations (c.5060C/T, p.S1687F in exon 30;
c.2014G/C, p.L1338F in exon 24 and c.4444T/G, p.T1482D
in exon 27, respectively). We checked whether the mutation
found on the DNA could be detected at the RNA level and
conﬁrmed the presence of the aberrant transcript beside the
normal one in all four cases. The comparative amino acid
sequence analysis revealed that all the mutations affect amino
acids that are highly conserved through evolution and in the
Table 1 Continued
Patient 41 75 99 114 20 46 98 84 127
Individual
clinical
signs
Corpus callosum
agenesis,
DandyeWalker
malformation
Duodenal
malrotation
First report 12 This study This study This study 12 12 This study This study This study
ASD, atrial septal defect; IUGR, intrauterine growth retardation; MR, mental retardation; NA, not assessed; PDA, patent ductus arteriosus; RSTS, RubinsteineTaybi syndrome.
Figure 1 Localisation of nine CREBBP
mutations (six of them of novel
description) in patients with
RubinsteineTaybi syndrome. A.
Schematic representation of the CBP
protein with its known domains: KIX
(CREB binding domain), BD
(bromodomain) and KAT
(acetyltransferase domain). The KAT
domain (aa 1232-1709) is depicted in
greater detail in the lower box indicating
its putative subdomains, namely, the
PHD (plant homeodomain-type zinc
finger) domain with enzymatic activity
(aa 1237-1311) and the coenzyme A
binding site (aa 1459-1541) B.
Localisation of the four missense
mutations (black symbols) within
CREBBP exons coding KAT domain; the
three splicing mutations in IVS1, IVS25
and IVS28 (grey symbols); the
truncating mutation in exon 13 (+) and
the whole gene deletion (x). C. Splicing
mutation of patient 99: reverse
transcriptase-PCR (RT-PCR) (top) of the
CREBBP fragment using primers in exon
1 (forward) and exon 2 (reverse)
evidencing two additional longer
fragments (asterisks). Diagram (bottom)
showing the localisation of two cryptic
donor sites leading to formation of two
aberrant transcripts retaining 411 and
519 bases of intron 1, respectively. D.
Splicing mutation of patient 114: RT-
PCR (top) of patient 114 using forward
and reverse primers in exons 22 and 29
showing two additional smaller
fragments (asterisks). Mechanism of
missplicing (bottom) leading to two
aberrant in-frame transcripts that, as
shown by the electropherograms, skip
exon 26 or exons 25 and 26. mw:
weight markers; nc: normal control.
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related p300 protein. All four missense mutations are located in
the KAT domain (ﬁgure 1A,B). In particular, the mutation of
patient 127 maps into the subdomain postulated to be the
coenzyme A binding site (amino acids 1459e1541). The muta-
tion carried by patient 46 has been conﬁrmed also in the DNA
isolated from the cheek and thigh where the patient developed
the benign epithelial tumours pilomatrixomas.
Splicing mutations
Patient 20, previously described,12 and the newly identiﬁed
patients 99 and 114 carry different types of splice site mutations.
The mutations found in patients 20 and 99 affect canonical
splicing sites and lead to the activation of cryptic exonic splice
sites, whereas the mutation of patients 114 affects a ‘non-
canonical’ splicing site. In all cases, we investigated the aberrant
CREBBP transcripts resulting from the missplicing. Patient 20
mutation, c.4728+1G/A, affecting the intervening sequence
(IVS) 28 donor splice site has been found to generate a transcript
skipping 104 bp of exon 28 through the activation of a cryptic
exonic donor site: the frameshift produced by missplicing should
lead to the incorporation of 38 anomalous amino acids.12 The
splice site mutation identiﬁed in patient 99 is a G/T substi-
tution in the ﬁrst base of IVS1 (85+1 G/T) arising de novo and
yet unreported. Bioinformatic analysis of the patient cDNA
predicted the presence of three different transcripts: the wild-
type one that appears to be expressed at the highest levels and
two longer transcripts. We sequenced the two aberrant tran-
scripts characterised by the retention of different portions of
IVS1 and found that the two transcripts originate from the
activation of two of the predicted donor sites with a highest
score after the canonical one (ﬁgure 1C). Translation of the two
aberrant transcripts is hypothesised to generate the same trun-
cated protein of 46 amino acids. Patient 114 carries the de novo
mutation c.4485-7C/G affecting the nucleotide at position 7 of
the consensus sequence in IVS25. According to Splice Site
Prediction, this substitution leads to a decrease of the score of
IVS25 acceptor site. cDNA analysis identiﬁed two aberrant
transcripts, one skipping exon 26 and one skipping exons 25 and
26 (ﬁgure 1D), that keep the same frame and encode proteins
lacking 49 and 87 aas, respectively.
Truncating mutation
Patient 75 carries a novel truncating mutation, c.2356delC in
exon 13 leading to frameshift and predicting the truncated
protein p.Q786RfsX20. RNA analysis evidenced the presence of
both transcripts: the normal and the aberrant originated by the
mutant allele.
Whole gene deletion
The deletion of patient 4112 20 encompasses a 500 kb region
beyond the 59 and 39 ends of the CREBBP gene.
B cells from these nine patients with RSTS were immortalised
using EpsteineBarr virus. For comparison purposes, we also
obtained lymphoblastoid cell lines from blood samples of three
normal individuals and three children with CdLS, a mental
retardation disorder molecularly unrelated to RSTS.
Expression of CREBBP and EP300 in cell lines from patients with
RSTS
We examined by qRT-PCR whether the mutations into the
CREBBP locus affected the level of CBP transcripts. These assays
revealed that the cell lines derived from seven of the nine
patients with RSTS showed the same level of CBP transcripts as
the control lines derived from healthy individuals and patients
with CdLS (ﬁgure 2A). Patient 41, who carries a complete
deletion of a CREBBP allele, had half-level of mRNA. Patient 20,
whose mutation produces an aberrant transcript lacking part of
exon 28,12 also showed a similar reduction of CBP transcript
since one of the primers used for qRT-PCR mapped in the
sequence missing in this patient. The absence of signiﬁcant
changes in the other lines indicates that despite the genomic
mutations, the mutant or truncated transcripts are stable and
have a similar transcription rate as the wild-type transcripts.
This was the case even for the cell line derived from patient 75,
who carries an early truncating mutation and likely produces
untranslatable transcripts potentially prone to accelerated decay.
We also tested whether CBP deﬁciency led to the upregulation of
EP300 expression given the high homology between these two
genes. P300-speciﬁc qRT-PCR assays in the 15 cell lines did not
reveal any signiﬁcant difference at the level of transcription,
indicating that there is no compensation of CBP reduction
through overexpression of p300 mRNA (ﬁgure 2B). Interestingly,
our qRT-PCR analysis indicates that the level of CBP transcripts
in these cells is almost one order of magnitude larger than for
p300 transcripts (ﬁgure 2C).
Chromatin acetylation deficits in cell lines from patients with
RSTS
We next obtained protein extracts from cultures in exponential
growth for each cell line and assessed for histone acetylation
deﬁcits through western blotting using an array of antibodies
raised against different Lys in the N-termini of histones H2A,
Figure 2 CBP and p300 transcript levels in RubinsteineTaybi
syndrome (RSTS) and control lymphoblastoid cell lines. AeB. mRNA
levels for CREBBP (A) and EP300 (B), normalised to GAPDH mRNA
levels, in the cell lines derived from patients with RSTS and control cell
lines (non-RSTS). White squares () depict cell lines derived from
healthy control individuals (CTRL), and white circles (B) represent cell
lines established from patients with CdLS. The symbol legend for RSTS
cell lines is at the bottom of the figure (see also figure 1B). Symbols in
the figure denote one cell line and represent the average of three to five
individual measurements. Cell line from patient 41 carries a whole gene
deletion of the CREBBP locus and shows a significant reduction of CBP
transcripts compared to control cell lines and to CdLS-derived cell lines
(*p<0.05, one-way analysis of variance followed by Tukey post hoc
test). n¼3e5 samples per group. C. The graph shows relative
abundance of CBP and p300 transcripts. Since the efficiency of the two
qRT-PCR primer pairs is the same, this result indicates that CBP is much
more highly expressed than p300 in the lymphoblastoid cell lines.
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H2B, H3 and H4. The acetylation test revealed signiﬁcant
differences in the level of histone H2A and H2B between the
cell lines derived from patients with RSTS (considered as
a group) and either one of the two control groups (ﬁgure 3). In
contrast, histones H3 and H4 showed levels of histone acetyla-
tion that did not differ from those observed in samples from
healthy controls and patients with CdLS. Our experiments also
revealed apparent differences between the different RSTS cell
lines. Whereas line RSTS41 showed robust histone acetylation
deﬁcits affecting several histones, most lines showed more
modest and speciﬁc deﬁcits, and line RSTS99 was not distin-
guishable from the control lines (table 2). In particular, we
observed the biggest deﬁcits in the lines derived from patients
41, 75, 127, 84 and 98.
Treatment with HDACi reverses the histone acetylation deficits
of RSTS-derived cells
The acetylation of histones is regulated by the counteracting
activity of KAT and histone deacetylase enzymes that respec-
tively add or remove acetyl groups from histones. We next tested
whether the treatment with an inhibitor of histone acetyl-
transferases (HDACi) reversed the hypoacetylation of histones.
Towards this end, we selected the cell line showing the largest
deﬁcit, RSTS41, and treated the cultures either with the HDACi
TSA or with the vehicle DMSO. Like previously reported for
CBP-deﬁcient mice,36 40 western blotting analysis of protein
extracts from cell cultures treated with TSA showed a level of
bulk histone H2B acetylation higher than that observed in
mutant and control cell lines treated with vehicle (ﬁgure 4A). To
Figure 3 Altered levels of histone
acetylation in cell lines from patients
with RubinsteineTaybi syndrome
(RSTS). A. Representative images of
western blot results showing protein
levels of acetylated chromatin core
histones H2A, H2B, H3, and H4, and
total levels of histones H2B and H3 and
b-actin in cell lysates from control
individuals and patients with RSTS
carrying mutations at the CREBBP
locus. BeG. Semiquantitative
densitometric analysis of western blots
showing significant reduction in AcH2A
and AcH2B levels in RSTS cell lines.
Experimental conditions and symbols as
in figure 2. Symbols in the figure denote
one cell line and represent the fold
change average value over control for
three to eight independent cultures; see
table 2 for statistical analysis of these
experiments. Protein levels in BeG are
expressed as fold change over control
upon normalisation for b-actin.
(*p<0.05, ManneWhitney U test).
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conﬁrm the rescue of the acetylation deﬁcit using an alternative
technique, we used ﬂow cytometry. Cells were ﬁxed, permea-
bilised, stained with anti-AcH2B antibody and analysed in
a FACSAria III cell sorter. We did not observe differences in the
forward scatter/side scatter distribution between genotypes or
treatments, indicating that TSA did not affect cell viability. This
experiment conﬁrmed the reduction of histone H2B acetylation
in cells derived from patient 41 when compared to a control cell
line and the reversal of the deﬁcit upon treatment with TSA
(ﬁgure 4BeC).
DISCUSSION
We reported here the identiﬁcation of six new mutations in the
CREBBP gene associated to RSTS, widening the spectrum of
mutations associated to this disorder. In addition, we investi-
gated the possible histone acetylation deﬁcits in lymphoblastoid
cell lines derived from nine patients carrying different types of
mutation in the CREBBP gene including those carrying the novel
mutations and three previously reported patients.12 20 We
observed deﬁcits in histone acetylation in most of these cell lines
that are similar to those observed in the brain of mice deﬁcient
in CBP activity, effectively translating seminal observations in
mouse models of RSTS to humans.
The examination of the acetylation state of the four nucleo-
some histones in the nine cell lines generated from individuals
with RSTS and the six lines from healthy individuals or
mentally impaired individuals with a different pathology
revealed consistent abnormalities. The acetylation assay of the
four nucleosome histones shows a general reduction of bulk
acetylation levels in patients with RSTS as compared to the
controls, particularly for histone H2B and H2A. The worst
deﬁcit was observed in the cell line from patient 41 bearing
a CBP null allele and showing severe mental retardation. Variable
acetylation deﬁcits were observed in patients that are carriers of
missense and splicing mutations. The cells from patients 98, 75,
127 and 114 showed signiﬁcant deﬁcits affecting the acetylation
state of more than one histone, whereas those from patients 20,
84 and 46 showed milder defects. Finally, the cells derived from
patient 99 (which carry a splicing mutation that predicts
a prematurely truncated protein) did not show any signiﬁcant
deﬁcit, although we cannot exclude that, in the absence of
apparent alterations at the bulk histone acetylation level, there
were defects in speciﬁc genomic loci. Given the very limited
impact of the splicing mutation in RSTS99 cells, we hypothesise
that the splicing alteration in this patient may be partial.
Although, in the most extreme examples, we observe certain
correlation between cognitive impairments and epigenetic
alterations in the cell lines, overall, it is difﬁcult to correlate the
severity of the molecular alterations and speciﬁc symptoms of
the disease. In line with the limited effect of some of the
mutations affecting the KAT domain in our analyses, two recent
studies using primary murine embryonic ﬁbroblasts from CBP/
p300 cre-deleted double knockout mice showed that mutant
CBP proteins carrying missense mutations that disrupt the KAT
domain, including mutations such as Q1500P, previously asso-
ciated to RSTS, still retain signiﬁcant KAT activity and
their expression only results in a modest reduction in H3K18
acetylation when compared to wild-type CBP.44 45
Although the role of CBP and p300 as KAT proteins has been
investigated in animal models of the disease, this represents the
ﬁrst study on acetylation capability performed in human cell
lines obtained from patients with RSTS who are carrier of
different CREBBP genetic lesions. The lack to access to diseased
neural tissue of patients with RSTS severely limits the trans-
lation of molecular observation in animal models to the clinic.
The use of peripheral blood and derived immortalised cell lines
can however provide some initial insight into the molecular
aetiology of the disease till the generation of RSTS-speciﬁc
induced pluripotent stem cells and their differentiation to
neurons.46 Thus, the detection of histone acetylation deﬁcits in
samples from patients with RSTS is of considerable value for
understanding the molecular aetiology of this disorder. It has
been suggested that histone acetylation/deacetylation in
neurons play a critical role in memory, addiction, neurogenesis
and other forms of neural plasticity.47 48 As a consequence, some
cognitive and physiological deﬁcits observed in RSTS may not
simply be due to defects originating during development, but
may result from the continued requirement of normal levels of
KAT activity throughout life.34
Interestingly, the experiments with an HDACi in two RSTS
cell lines showing signiﬁcant deﬁcits in the acetylation of
histone H2B demonstrated a rescue of the defect, conﬁrming the
Table 2 Summary of the densitometric analysis of immunoblots against histone levels in cell lines from patients with RSTS
Patient 41 75 99 114 20 46 98 84 127
Mutation/type Whole gene
deletion
microdeletion
c.2556delC
p.Gln786ArgfsX21
truncating
c.85+
1G/T
splicing
c.4485-
7C/G
splicing
c.4728+
1G/A
splicing
c.4627G/T
p. Asp1543Tyr
missense
c.2014G/C
p.Leu1338Phe
missense
c.5060C/T
p.Ser1687Phe
missense
c.4444T/G
p.Tyr1482Asp
missense
Lymphoblastoid
cell line
RSTS41 RSTS75 RSTS99 RSTS114 RSTS20 RSTS46 RSTS98 RSTS84 RSTS127
AcH2A 0.51±0.35 0.7660.26 0.9360.19 0.68±0.38 0.9460.25 0.9060.31 0.72±0.17 0.65±0.19 0.64±0.18
F10,78¼2.53; p¼0.012 p<0.001 NS NS p<0.05 NS NS p[0.05 p<0.05 p<0.05
AcH2B 0.34±0.14 0.77±0.21 0.9660.05 0.9660.63 0.66±0.27 0.74±0.21 0.7±0.14 0.8460.25 0.48±0.14
F10,75¼5.93; p¼2.6E-6 p<0.001 p<0.05 NS NS p<0.01 p<0.01 p<0.05 NS p<0.001
AcH3 0.56±0.35 0.8660.24 1.260.13 0.72±0.33 0.9360.14 0.9260.18 0.8860.19 0.7560.2 0.7860.15
F10,64¼2.7; p¼0.009 p<0.001 NS NS p[0.05 NS NS NS NS NS
AcH4 0.660.36 0.43±0.21 1.3660.01 0.9460.88 0.9060.4 1.2460.38 0.4860.12 0.7560.63 0.9960.2
F10,49¼2.02; p¼0.057 NS p<0.05 NS NS NS NS NS NS NS
H2B 0.9860.04 160.13 1.0160.03 1.0860.08 1.0960.1 0.9560.18 0.8460.13 0.9160.01 0.9560.02
F10,49¼0.65; p¼0.76 NS NS NS NS NS NS NS NS NS
H3 0.960.32 0.9560.07 1.1860.22 0.9660.24 0.9360.06 1.0960.32 0.8160.16 1.0360.2 0.8160.15
F10,58¼0.93; p¼0.52 NS NS NS NS NS NS NS NS NS
Data are expressed as means6SEM. Significant differences between groups (one-way analysis of variance followed by Fisher’s protected least significant difference post hoc test) are shown
in bold.
n¼3e8 samples per group.
NS, not significant.
Lopez-Atalaya JP, Gervasini C, Mottadelli F, et al. J Med Genet (2011). doi:10.1136/jmedgenet-2011-100354 7 of 9
Phenotypes
 group.bmj.com on November 24, 2011 - Published by jmg.bmj.comDownloaded from 
plasticity of the acetylation state and the possibility of modu-
lating it, and paving the way to the idea of a therapeutic
treatment of RSTS. Given the proven efﬁcacy of HDACi,
including TSA, in RSTS mouse models,36 37 49 the conﬁrmation
of the existence of similar biochemical deﬁcits in cell lines from
patients and their reversal by HDACi open new therapeutic
possibilities. There is great interest in the pharmaceutical
industry for developing ‘epi-drugs’ suitable for treating brain
diseases.50 Various histone deacetylases, more speciﬁc and
showing less noxious side effects than TSA, are currently being
tested for the treatment of different forms of cancer and
neurodegeneration. If the results of these clinical trials were
positive and the new compounds show minimal side effects, it
would be worthwhile to test their effectiveness also in the
treatment of RSTS.
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